NasdaqGM:SMMTBiotechs
Is It Too Late To Consider Summit Therapeutics (SMMT) After A 3x Three-Year Surge?
If you are wondering whether Summit Therapeutics at US$19.68 is starting to look expensive or still offers value, you are not alone.
The stock has had a strong run, with returns of 12.8% over the last 7 days, 12.0% over the last 30 days, 12.3% year to date, 8.3% over 1 year and about 3x over 3 years. The 5 year return sits at 271.3%.
Recent attention on Summit Therapeutics has been driven by ongoing interest in its pipeline and partnerships within the pharmaceuticals and biotech space. This...